ESTERO, FL / ACCESS Newswire / November 26, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) (“Aspire” or the “Company”), a developer of a multi-faceted patent-pending drug delivery technology, ...
Zenas BioPharma, Inc. provided an update on its clinical programs and financial results for the first quarter of 2025. The Company anticipates topline results from its pivotal Phase 3 INDIGO trial for ...
“Dr. Jaroszeski is recognized globally for his pioneering work in DNA and drug delivery, and we are honored to welcome him to the Aspire team,” said Kraig Higginson, Interim CEO of Aspire Biopharma.
ESTERO, FL / ACCESS Newswire / November 26, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback